Rifaximin (Xifaxan)

DRUG6 trials

Conditions

Clostridium InfectionsColon SurgeryDiarrheaMetabolic-associated Fatty Liver DiseaseRosaceaSmall Intestinal Bacterial Overgrowth Syndrome (SIBO)Surgical Site InfectionSurgical Site Infections

Early Phase 1

Efficacy and Safety of Rifaximin in Treating MAFLD

RecruitingNCT07185932

Shanghai Changzheng HospitalMetabolic-associated Fatty Liver Disease

Start: 2024-08-10End: 2027-12-31Target: 40Updated: 2025-09-22

Phase 2

Rifaximin Treatment of Papulopustular Rosacea

WithdrawnNCT01359228

University of California, San FranciscoRosacea

Start: 2013-04-30End: 2014-12-31Updated: 2014-04-28

Phase 3

A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

CompletedNCT00269399

Bausch Health Americas, Inc.Clostridium Infections, Diarrhea

Start: 2005-12-31End: 2008-12-31Updated: 2019-10-14

A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.

TerminatedNCT02920242

SandozTravelers' Diarrhea

Start: 2016-12-15End: 2017-05-23Updated: 2019-03-25

Phase 4

Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery

Not yet recruitingNCT07180615

Universität LuzernColon Surgery, Surgical Site Infection, Surgical Site Infections

Start: 2026-06-01End: 2029-06-30Target: 458Updated: 2025-09-18

Comparison of the Efficacy of Saccharomyces Boulardii and Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth

Not yet recruitingNCT07815548

Shandong UniversitySmall Intestinal Bacterial Overgrowth Syndrome (SIBO)